发布求助
文献互助 智能选刊 最新文献

Journal of Law Medicine & Ethics最新文献

筛选
英文 中文
Socioeconomic Factors in Brain Research: Increasing Sample Representativeness with Portable MRI. 脑研究中的社会经济因素：便携式MRI增加样本代表性。
IF 1.6 4区 哲学
Journal of Law Medicine & Ethics Pub Date : 2024-01-01 Epub Date: 2025-01-31 DOI: 10.1017/jme.2024.168
Martha J Farah
{"title":"Socioeconomic Factors in Brain Research: Increasing Sample Representativeness with Portable MRI.","authors":"Martha J Farah","doi":"10.1017/jme.2024.168","DOIUrl":"10.1017/jme.2024.168","url":null,"abstract":"<p><p>People of low socioeconomic status (SES) are often underrepresented in biomedical research. The importance of demographically diverse research samples is widely recognized, especially given socioeconomic disparities in health, but have been challenging to achieve. One barrier to research participation by low SES individuals is their distance from research centers and the difficulty of traveling. This article examines the promise of portable magnetic resonance imaging (pMRI) for enrolling participants of diverse SES in structural neuroimaging studies, and anticipates some of the challenges, practical and ethical, that may arise in the course of such research.</p>","PeriodicalId":50165,"journal":{"name":"Journal of Law Medicine & Ethics","volume":"52 4","pages":"824-829"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11798670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenges for the Pro-Life Movement in a Post-Roe Era - ERRATUM. 后罗伊时代支持生命运动面临的挑战 - ERRATUM.
IF 1.6 4区 哲学
Journal of Law Medicine & Ethics Pub Date : 2024-01-01 Epub Date: 2024-02-26 DOI: 10.1017/jme.2024.32
Cathleen Kaveny
{"title":"Challenges for the Pro-Life Movement in a Post-<i>Roe</i> Era - ERRATUM.","authors":"Cathleen Kaveny","doi":"10.1017/jme.2024.32","DOIUrl":"10.1017/jme.2024.32","url":null,"abstract":"","PeriodicalId":50165,"journal":{"name":"Journal of Law Medicine & Ethics","volume":" ","pages":"207"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139974257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
INTRODUCTION: Medical-Legal Partnerships: Equity, Evolution, and Evaluation - CORRIGENDUM. 简介：医学与法律的伙伴关系：公平、演变和评估》 - CORRIGENDUM.
IF 1.6 4区 哲学
Journal of Law Medicine & Ethics Pub Date : 2024-01-01 Epub Date: 2024-04-16 DOI: 10.1017/jme.2024.50
Katherine L Kraschel, James Bhandary-Alexander, Yael Z Cannon, Vicki W Girard, Abbe R Gluck, Jennifer L Huer, Medha D Makhlouf
{"title":"INTRODUCTION: Medical-Legal Partnerships: Equity, Evolution, and Evaluation - CORRIGENDUM.","authors":"Katherine L Kraschel, James Bhandary-Alexander, Yael Z Cannon, Vicki W Girard, Abbe R Gluck, Jennifer L Huer, Medha D Makhlouf","doi":"10.1017/jme.2024.50","DOIUrl":"10.1017/jme.2024.50","url":null,"abstract":"","PeriodicalId":50165,"journal":{"name":"Journal of Law Medicine & Ethics","volume":" ","pages":"208"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140871031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
"A Most Equitable Drug": How the Clinical Studies of Convalescent Plasma as a Treatment for SARS-CoV-2 Might Usefully Inform Post-Pandemic Public Sector Approaches to Drug Development. "最公平的药物"：将康复血浆作为治疗 SARS-CoV-2 的临床研究如何为大流行后公共部门的药物开发方法提供有用信息。
IF 1.6 4区 哲学
Journal of Law Medicine & Ethics Pub Date : 2024-01-01 Epub Date: 2024-05-31 DOI: 10.1017/jme.2024.51
Quinn Grundy, Chantal Campbell, Ridwaanah Ali, Matthew Herder, Kelly Holloway
{"title":"\"A Most Equitable Drug\": How the Clinical Studies of Convalescent Plasma as a Treatment for SARS-CoV-2 Might Usefully Inform Post-Pandemic Public Sector Approaches to Drug Development.","authors":"Quinn Grundy, Chantal Campbell, Ridwaanah Ali, Matthew Herder, Kelly Holloway","doi":"10.1017/jme.2024.51","DOIUrl":"10.1017/jme.2024.51","url":null,"abstract":"<p><p>Interventional clinical studies of convalescent plasma to treat COVID-19 were predominantly funded and led by public sector actors, including blood services operators. We aimed to analyze the processes of clinical studies of convalescent plasma to understand alternatives to pharmaceutical industry biopharmaceutical research and development, particularly where public sector actors play a dominant role. We conducted a qualitative, critical case study of purposively sampled prominent and impactful clinical studies of convalescent plasma during 2020-2021.</p>","PeriodicalId":50165,"journal":{"name":"Journal of Law Medicine & Ethics","volume":"52 1","pages":"80-97"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141181256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Strategy, Morality, Courage: Bioethics and Health Law after Dobbs. 战略、道德、勇气：多布斯之后的生命伦理学和卫生法》。
IF 1.6 4区 哲学
Journal of Law Medicine & Ethics Pub Date : 2024-01-01 Epub Date: 2024-10-22 DOI: 10.1017/jme.2024.104
Nancy M P King, Christine Nero Coughlin, Beverly J Levine
{"title":"Strategy, Morality, Courage: Bioethics and Health Law after <i>Dobbs</i>.","authors":"Nancy M P King, Christine Nero Coughlin, Beverly J Levine","doi":"10.1017/jme.2024.104","DOIUrl":"10.1017/jme.2024.104","url":null,"abstract":"<p><p>Our paper examines what is required to protect and promote effective public discussion and policy development in the current climate of divisive disagreement about many public policy questions. We use abortion as a case example precisely because it is morally fraught. We first consider the changes made by <i>Dobbs</i>, as well as those which led up to the <i>Dobbs</i> decision, accompany it, and follow from it.</p>","PeriodicalId":50165,"journal":{"name":"Journal of Law Medicine & Ethics","volume":"52 2","pages":"290-308"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Supreme Court Impacts in Public Health Law: 2023-2024. 最高法院对公共卫生法的影响：2023-2024 年。
IF 1.6 4区 哲学
Journal of Law Medicine & Ethics Pub Date : 2024-01-01 Epub Date: 2024-10-22 DOI: 10.1017/jme.2024.120
James G Hodge, Jennifer L Piatt, Erica N White, Leila F Barraza, Kyrah M Berthiaume
{"title":"Supreme Court Impacts in Public Health Law: 2023-2024.","authors":"James G Hodge, Jennifer L Piatt, Erica N White, Leila F Barraza, Kyrah M Berthiaume","doi":"10.1017/jme.2024.120","DOIUrl":"10.1017/jme.2024.120","url":null,"abstract":"<p><p>In a \"mixed bag\" 2023-2024 session, the U.S. Supreme Court issued a series of decisions both favorable and antithetical to public health and safety. Taking on tough constitutional issues implicating gun control, misinformation, and homelessness, the Court also avoided substantive reviews in favor of procedural dismissals in key cases involving reproductive rights and government censorship.</p>","PeriodicalId":50165,"journal":{"name":"Journal of Law Medicine & Ethics","volume":"52 2","pages":"484-487"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Telehealth after the Federal COVID-19 Public Health Emergency: Implications and Future Directions. 联邦 COVID-19 公共卫生紧急事件后的远程医疗：影响和未来方向。
IF 1.6 4区 哲学
Journal of Law Medicine & Ethics Pub Date : 2024-01-01 Epub Date: 2024-10-22 DOI: 10.1017/jme.2024.118
Minsoo Kwon, James René Jolin, Carmel Shachar
{"title":"Telehealth after the Federal COVID-19 Public Health Emergency: Implications and Future Directions.","authors":"Minsoo Kwon, James René Jolin, Carmel Shachar","doi":"10.1017/jme.2024.118","DOIUrl":"10.1017/jme.2024.118","url":null,"abstract":"<p><p>May 11, 2023, marked the end of the federal COVID-19 Public Health Emergency (PHE). During the PHE, regulatory flexibilities allowed telehealth to more effectively connect physicians providing care and patients seeking it. This paper discusses the implications of the end of the PHE on telehealth coverage, payment, reimbursement, and licensure, and exposes inconsistencies and inequities in extant state regulations.</p>","PeriodicalId":50165,"journal":{"name":"Journal of Law Medicine & Ethics","volume":"52 2","pages":"412-418"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative Analysis of Drug Shortages in the US and Germany (2016 - 2023). 美国和德国药物短缺对比分析（2016 - 2023 年）》。
IF 1.6 4区 哲学
Journal of Law Medicine & Ethics Pub Date : 2024-01-01 Epub Date: 2024-10-22 DOI: 10.1017/jme.2024.105
Emanuel Nussli, Miquel Serra-Burriel, Kerstin N Vokinger
{"title":"Comparative Analysis of Drug Shortages in the US and Germany (2016 - 2023).","authors":"Emanuel Nussli, Miquel Serra-Burriel, Kerstin N Vokinger","doi":"10.1017/jme.2024.105","DOIUrl":"10.1017/jme.2024.105","url":null,"abstract":"<p><p>This article analyzes trends in drug shortages in the US and Germany, the largest pharmaceutical market in Europe, between 2016 and 2023. It assesses the commonalities and differences between the countries in terms of active substances in shortage, time duration in shortage, and cyclic trends.</p>","PeriodicalId":50165,"journal":{"name":"Journal of Law Medicine & Ethics","volume":"52 2","pages":"488-497"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent Claim Scope and Biosimilar Competition in the US and EU. 美国和欧盟的专利权利要求范围与生物仿制药竞争。
IF 1.6 4区 哲学
Journal of Law Medicine & Ethics Pub Date : 2024-01-01 Epub Date: 2024-10-22 DOI: 10.1017/jme.2024.133
Doni Bloomfield, Aaron S Kesselheim
{"title":"Patent Claim Scope and Biosimilar Competition in the US and EU.","authors":"Doni Bloomfield, Aaron S Kesselheim","doi":"10.1017/jme.2024.133","DOIUrl":"10.1017/jme.2024.133","url":null,"abstract":"<p><p>The US has found it hard to establish competition in the market for biologics, which are therapeutics derived from living cells. In the case of small-molecule drugs, the emergence of direct competition from generic drugs at the end of the exclusivity period has provided the impetus for price competition, leading to lower spending. In 2010, to spur competition in the biologics market, Congress created a simplified pathway for the US Food and Drug Administration (FDA) to approve comparable versions of biologic drugs called biosimilars. Biosimilar competition in the US has nonetheless remained weaker than in European peer countries. For example, as of August 2020, there were 52 biosimilars available in Germany, and only 15 in the US.<sup>1</sup> An important contributor to this \"biosimilar gap\" has been the fact that biosimilars to biologic blockbusters such as adalimumab (Humira) and etanercept (Enbrel) were only (or will only become) commercially available in the US several years after receiving FDA approval, while they were available in Europe years earlier.<sup>2</sup> Through the end of 2021, it took biosimilars a median of 301 days between receiving FDA approval and becoming available for use.<sup>3</sup> In one recent study, the median length of time between when a biologic drug was approved and when its first biosimilar was made available to US patients was 21.5 years.<sup>4</sup> This paucity of competition has contributed to high US spending on biologics. According to the Department of Health and Human Services, in 2022 41% of US drug expenditures was spent on biologics, which represented 16% of US prescriptions.<sup>5</sup>.</p>","PeriodicalId":50165,"journal":{"name":"Journal of Law Medicine & Ethics","volume":"52 2","pages":"439-442"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter From The Editor. 编辑来信
IF 1.6 4区 哲学
Journal of Law Medicine & Ethics Pub Date : 2024-01-01 Epub Date: 2024-12-16 DOI: 10.1017/jme.2024.145
Ted Hutchinson
{"title":"Letter From The Editor.","authors":"Ted Hutchinson","doi":"10.1017/jme.2024.145","DOIUrl":"10.1017/jme.2024.145","url":null,"abstract":"","PeriodicalId":50165,"journal":{"name":"Journal of Law Medicine & Ethics","volume":"52 3","pages":"523"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142830730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信